64291-45-8
Chemical Structure
Detorubicin hydrochloride
Synonym(s): NSC 292652 hydrochloride; RP 33921 hydrochloride
- CAS No.: 64291-45-8
- Formula:C33H40ClNO14
- Molecular Weight:710.12
IUPAC Name: 2-((2S,4S)-4-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-oxoethyl 2,2-diethoxyacetate hydrochloride
InChIKey: PJODMULXZJQLDJ-NMELVCTCSA-N
SMILES: OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(COC(C(OCC)OCC)=O)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N.Cl
Biological Activity: Detorubicin hydrochloride (NSC 292652 hydrochloride) is a semi-synthetic analog of Daunorubicin (HY-13062A) and a prodrug of Doxorubicin (HY-15142A). Detorubicin hydrochloride hydrolyzes to release Doxorubicin under neutral pH conditions. Detorubicin hydrochloride forms complexes with DNA. Detorubicin hydrochloride exhibits anti-hematologic tumor and metastatic melanoma activities. Detorubicin hydrochloride causes myocardial injury, skin damage, alopecia, and high mortality in golden hamsters. Detorubicin hydrochloride can be used in research related to leukemia, and metastatic melanoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Detorubicin hydrochloride | Detorubicin hydrochloride (NSC 292652 hydrochloride) is a semi-synthetic analog of Daunorubicin (HY-13062A) and a prodrug of Doxorubicin (HY-15142A). Detorubicin hydrochloride hydrolyzes to release Doxorubicin under neutral pH conditions. Detorubicin hydrochloride forms complexes with DNA. Detorubicin hydrochloride exhibits anti-hematologic tumor and metastatic melanoma activities. Detorubicin hydrochloride causes myocardial injury, skin damage, alopecia, and high mortality in golden hamsters. Detorubicin hydrochloride can be used in research related to leukemia, and metastatic melanoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zenebergh A, et al. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells. European journal of cancer & clinical oncology. 1984 Jan;20(1):115-21. [Content Brief]
- [2]. Chawla SP, et al. Detorubicin--an active anthracycline in untreated metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1985 Nov;3(11):1529-34. [Content Brief]
- [3]. Trouet A, et al. Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data. Cancer Chemother Pharmacol. 1979;2(1):77-9. [Content Brief]
- [4]. Dantchev D, et al. Ultrastructural study of the cardiotoxicity and light-microscopic findings of the skin after treatment of golden hamsters with seven different anthracyclines. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1980;74:223-49. [Content Brief]
Keywords
